Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NT69L is a synthetic hexapeptide analog of the neurotensin (8-13) fragment that acts as a potent and nonselective agonist at neurotensin receptors NTS1 and NTS2. NT69L exhibits atypical antipsychotic-like properties in animal models, including the ability to block disruptions of prepulse inhibition and hyperactivity induced by psychostimulants such as amphetamine and DOI, effects consistent with antipsychotic agents. NT69L also increases dopamine and acetylcholine efflux in the medial prefrontal cortex and can block reinstatement of cocaine preference, supporting research into its utility for schizophrenia, psychosis, and substance use disorders[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NT69L.